Physician profile
Kevin Yang
NPI 1518547330
$5,066.78
in general payments reported to CMS, 2019-2025
17 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $771 · 2023: $705 · 2024: $2,090 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,130 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,130.42 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $855.73 | 2022-2025 | Rinvoq |
| Lilly USA, LLC | $590.47 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $576.47 | 2023-2025 | |
| Pfizer INC. | $446.93 | 2022-2025 | |
| Incyte Corporation | $391.31 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $388.35 | 2022-2024 | Twyneo, Aklief |
| Genzyme Corporation | $299.60 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.82 | 2022-2024 | Spevigo |
| Ucb, INC. | $272.77 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $260.55 | 2022-2023 | Libtayo |
| Janssen Biotech, INC. | $209.92 | 2023-2024 | Tremfya |
| Dermavant Sciences, INC. | $189.22 | 2023-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $98.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $84.76 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $43.22 | 2025 | Zoryve |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $39.12 | 2024-2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $21.61 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.